Literature DB >> 34507827

Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.

Zhenkun Wang1, Ensong Guo2, Bin Yang2, Rourou Xiao2, Funian Lu2, Lixin You2, Gang Chen3.   

Abstract

BACKGROUND: Gynecologic cancers seriously threaten women's life and health. This study aims to assess the long-term trends of mortality from the three major gynecologic cancers in China and to examine the age-, period-, and cohort-specific effects behind them during the period 1990 to 2019.
METHODS: The mortality data of cervical, ovarian, and uterine cancer in China were obtained from the Global Burden of Disease Study 2019 and were analyzed with the age-period-cohort framework.
RESULTS: It was found that the net drift for cervical cancer mortality was -0.19% (95% CI, -0.46% to 0.08%) per year, for ovarian cancer was 0.76% (95% CI, 0.57% to 0.95%) per year, and for uterine cancer was -3.09% (95% CI, -3.44% to -2.76%) per year from 1990 to 2019. During this period, while cervical cancer remained the most common cause of death among gynecologic cancers among Chinese women, ovarian cancer replaced uterine cancer as the second leading cause of death in gynecologic cancers after about 2005. Significant age, cohort, and period effects were found for the mortality trends of all three major gynecologic cancers.
CONCLUSIONS: The secular trends of mortality from the three major gynecologic cancers in China and their underlying age, period, and cohort effects are likely to reflect the progress of diagnosis and treatment, rapid socio-economic transitions, and the accompanying lifestyle and behavior changes. More priorities of further epidemiology studies and efforts on the prevention and control should be given to three major gynecologic cancers.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Cervical cancer; China; Mortality trend; Ovarian cancer; Uterine cancer

Mesh:

Year:  2021        PMID: 34507827     DOI: 10.1016/j.ygyno.2021.08.029

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer.

Authors:  Xiao-Mei Zhang; Xin-Yu Zhang; Yue-Xi Liu; Ruo-Nan Li; Yong-Mei Li; Hua Linghu
Journal:  Abdom Radiol (NY)       Date:  2022-04-05

2.  The Human Papillomavirus Infection Characteristics for Patients with Cervical Intraepithelial Neoplasia in Yunnan, China: A Sampling Survey Analysis.

Authors:  Hong-Fang Zhi; Liu-Feng Yang; Jing Ge; Xuan-Tao Yang
Journal:  Infect Drug Resist       Date:  2022-06-01       Impact factor: 4.177

3.  The risk of distant metastases in patients with gynecologic cancers after surgery: a population-based study.

Authors:  Yi-Hsuan Hsiao; Pei-Ni Chen; Min-Chien Hsin; Po-Hui Wang; Jing-Yang Huang; Shun-Fa Yang
Journal:  Aging (Albany NY)       Date:  2021-12-16       Impact factor: 5.682

4.  A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.

Authors:  Shuai Zong; Ping-Ping Xu; Yin-Hai Xu; Yi Guo
Journal:  J Ovarian Res       Date:  2022-08-01       Impact factor: 5.506

5.  A qualitative study of psychological stress among China's frontline nurses fighting COVID-19.

Authors:  Aihong Pan; Yuyan Wu; Xiaoju Chen; Weihua Yu; Xufeng Wu; Lili Chen; Lei He; Guohua Zheng; Li Ma
Journal:  Arch Med Sci       Date:  2022-07-08       Impact factor: 3.707

6.  Correlation between the neutrophil-to-lymphocyte ratio and clinicopathological parameters in epithelial ovarian cancer patients and its effect on prognosis-a retrospective cohort study.

Authors:  Juan Dong; Hui Xue; Fengwei An; Yuanyuan Liu; Wei Deng; Qin Gao
Journal:  Gland Surg       Date:  2022-08

7.  Norcantharidin induces ferroptosis via the suppression of NRF2/HO-1 signaling in ovarian cancer cells.

Authors:  Xiaoyan Zhu; Xiaohong Chen; Longshan Qiu; Jianhua Zhu; Jiancai Wang
Journal:  Oncol Lett       Date:  2022-08-25       Impact factor: 3.111

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.